logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
Targeted Oncology 封面图

Targeted Oncology

IF4
论文数1225
被引数2514
期刊论文 1225
发表时间
delete
Real-World Safety and Effectiveness of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: Final Analysis of the RAPIT StudyRadium-223在转移性去势抵抗性前列腺癌患者中的真实世界安全性与有效性：RAPIT研究的最终分析
deleteTargeted Oncology
IF4
delete2026-10-25
delete0
PREAI
deleteChao-Yuan Huang; Chi-Ping Huang; Yu-Yi Huang; Steven Kuan-Hua Huang; Kevin Lu; En Meng; Shu-Pin Huang; Ming-Yang Lee; Sheng-Chun Hung; Frank Chen; See-Tong Pang
delete分享
delete收藏
Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study评估奥拉帕利在BRCA突变、激素受体阳性、HER2阴性转移性乳腺癌患者中CDK4/6抑制剂治疗后的疗效：土耳其肿瘤学组（TOG）研究
deleteTargeted Oncology
IF4
delete2026-10-22
delete0
PREAI
deleteZeynep Sıla Gökdere; Taha Koray Şahin; İrem Bilgetekin; Naziyet Köse Baytemur; Mustafa Seyyar; Melike Yazıcı; Ercan Gümüşburun; Seval Akay; Damla Günenç; Çağla Karaoğlu; Pınar Ezgi Dama; Ece Şahin Hafızoğlu; Serkan Menekşe; Berkan Karadurmuş; Talha Özüdoğru; Galip Can Uyar; Görkem Turhan; Bahadır Köylü; Ferit Turan; Ayşe Nuransoy Cengiz; Ali Kaan Güren; Osman Bütün; Cevher Burcu Salman; Aslı Geçgel; Şüheda Ataş İpek; Esra Asarkaya; Bedriye Açıkgöz Yıldız; Ahmet Ünlü; Elif Şahin; Ekin Akyıldız Usta; Hüseyin Kanmaz; Ece Esin; Engin Erdemoğlu; Atilla Yıldırım; Musa Barış Aykan; Tülay Kuş; Mustafa Şahbazlar; Erdem Çubukçu; Hüseyin Salih Semiz; Fatih Selçukbiricik; Mevlüde İnanç; Murat Sarı; Bülent Karabulut; Hatice Odabaş; Ertuğrul Bayram; Gamze Gököz Doğu; Banu Öztürk; Zeynep Gülsüm Güç; Ulus Ali Şanlı; Burcu Çakar; Erhan Gökmen; Berna Çakmak Öksüzoğlu; Devrim Çabuk; Sercan Aksoy; Hasan Çağrı Yıldırım
delete分享
delete收藏
Treatment Trends and Survival Outcomes in Clinical Stage III Melanoma: Real-World Analysis of NCDB Data临床III期黑色素瘤的治疗趋势与生存结局：NCDB数据的真实世界分析
deleteTargeted Oncology
IF4
delete2026-10-22
delete0
deleteOAAI
deleteDaniel Park; Helena T. Wu; Dani R. Castillo; Kelly Mahuron; Arya Amini; Krupal Patel; Badri Modi; Ravi Salgia; Edward W. Wang; Vijay Trisal; Mengni Guo; S. Peter Wu; Yan Xing
delete分享
delete收藏
Efficacy and Safety of Infliximab for Management of Immune-Related Adverse Events: A Retrospective Analysis英夫利昔单抗在管理免疫相关不良事件中的有效性与安全性：一项回顾性分析
deleteTargeted Oncology
IF4
delete2026-10-21
delete0
deleteOAAI
deleteFilippos Koutroumpakis; Yifan Xu; Kevin Shi; Kei Takigawa; Irene Jeong-Ah Lee; Anirudha Chatterjee; Sidra Naz; Yilin Song; Monica Desai; Mohamed Gouda; Jessica Philpott; Yinghong Wang
delete分享
delete收藏
Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer维布司妥利单抗与帕博利珠单抗联合化疗作为广泛期小细胞肺癌的一线治疗方案
deleteTargeted Oncology
IF4
delete2026-10-20
delete0
deleteOAAI
deleteJacob Sands; Shun Lu; Joachim G. Aerts; Martin Reck; Alejandro Navarro; Talia Shentzer Kutiel; Nir Peled; Ignacio Casarini; Samuel J. Kerr; Toshiaki Takahashi; Ahmet Bilici; Ying Cheng; Mengzhao Wang; Shin Yup Lee; Anna Łowczak; Julien Mazieres; Haixia Hu; Jianyu Wu; Himani Aggarwal; Hazem El-Osta; Luis Paz-Ares
delete分享
delete收藏
Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit–Risk Assessment肾细胞癌根治性肾切除术后辅助全身治疗的贝叶斯网络荟萃分析及多标准获益-风险评估
deleteTargeted Oncology
IF4
delete2026-10-18
delete0
PREAI
deleteShugo Yajima; Gaku Okumura; Soichiro Yoshida; Hiroshi Fukushima; Hiroyuki Sato; Akihiro Hirakawa; Toshiki Kijima; Hitoshi Masuda; Yasuhisa Fujii
delete分享
delete收藏
Association of TP53 Truncating Mutations with Time to Treatment Failure after First-Line Chemoimmunotherapy in HER2-Mutant Non-Small Cell Lung CancerTP53截断突变与HER2突变非小细胞肺癌一线化疗免疫治疗后至治疗失败时间的相关性
deleteTargeted Oncology
IF4
delete2026-10-17
delete0
PREAI
deleteAkihiro Yoshimura; Juichiro Yoshida; Chieko Takumi; Koichi Takayama
delete分享
delete收藏
A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives关于奥希替尼在不可切除的III期EGFR突变非小细胞肺癌（NSCLC）中CRT后的播客：当前和未来展望
deleteTargeted Oncology
IF4
delete2026-10-13
delete0
deleteOAAI
deleteThanyanan Reungwetwattana; Kristin A. Higgins; Ignacio Casarini; Suresh S. Ramalingam
delete分享
delete收藏
Comment on: “First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies”评述：“KPT-9274首次人体I期研究，一种首创的PAK4和NAMPT双重抑制剂，在晚期实体恶性肿瘤患者中的研究”
deleteTargeted Oncology
IF4
delete2026-10-07
delete0
PREAI
deleteReza Izadpanah; Eckhard U. Alt
delete分享
delete收藏
Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast默克尔细胞癌中10年免疫检查点抑制剂的研究进展：一个播客
deleteTargeted Oncology
IF4
delete2026-10-07
delete0
deleteOAAI
deleteShailender Bhatia; Sandra D’Angelo; Paul Nghiem
delete分享
delete收藏
Beyond Contraindication-Based Selection: The Unmet Need for Predictive Biomarkers in First-Line Immunotherapy for Advanced HCC超越禁忌症为基础的选择：晚期肝癌一线免疫治疗中预测性生物标志物的未满足需求
deleteTargeted Oncology
IF4
delete2026-10-04
delete0
PREAI
deleteAlireza Tojjari; Anwaar Saeed
delete分享
delete收藏
Correction: Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure更正：瑞戈非尼作为二线治疗与后线治疗在晚期肝细胞癌中的应用：一项多中心真实世界研究及对先前免疫检查点抑制剂暴露的探索性分析
deleteTargeted Oncology
IF4
delete2026-10-02
delete0
PREAI
deleteKwon Yong Tak; Hee Sun Cho; Jaejun Lee; Kyeungmo Yang; Ahlim Lee; Ji Won Han; Soon Kyu Lee; Hyun Yang; Heechul Nam; Hee Yeon Kim; Sung Won Lee; Seok-Hwan Kim; Do Seon Song; Myeong Jun Song; Jung Hyun Kwon; UIm Chang; Soon Woo Nam; Chang Wook Kim; Jeong Won Jang; Si Hyun Bae; Hae Lim Lee; Pil Soo Sung
delete分享
delete收藏
Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort StudyPD-L1高表达肿瘤的患病率及其与转移性尿路上皮癌患者一线治疗效果的关联：一项前瞻性观察队列研究的结果
deleteTargeted Oncology
IF4
delete2026-10-02
delete0
deleteOAAI
deletePetros Grivas; Piyush K. Agarwal; Hikmat Al-Ahmadie; Terence Friedlander; Daniel M. Geynisman; Yair Lotan; Alicia K. Morgans; Fernando J. Bianco; Sreenivasa Chandana; Bruno Fang; Michael Large; Joshua J. Meeks
delete分享
delete收藏
Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast CancerHER2CLIMB-05研究总结：曲拉妥尼（Tucatinib）对比安慰剂联合曲妥珠单抗和帕妥珠单抗用于HER2阳性转移性乳腺癌的一线维持治疗的三期研究
deleteTargeted Oncology
IF4
delete2026-09-19
delete0
deleteOAAI
deleteVeronique Dieras; Giuseppe Curigliano; Miguel Martin; Florence Lerebours; Junji Tsurutani; Marie-France Savard; Katarzyna J. Jerzak; Xichun Hu; Ciara C. O’Sullivan; Eriko Tokunaga; Alicia Okines; Chiun-Sheng Huang; William Jacot; Joohyuk Sohn; Eduardo Cronemberger Silva; Volkmar Mueller; Shan Yang; Giovanna Granata; Qi Shen; Erika Hamilton
delete分享
delete收藏
Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab OzogamicinB-细胞前体急性淋巴细胞白血病患者使用奥英妥珠单抗治疗后的预后与体重指数的关系
deleteTargeted Oncology
IF4
delete2026-09-16
delete0
deleteOAAI
deleteWendy Stock; Ryan D. Cassaday; Daniel J. DeAngelo; Anjali Advani; Nicola Gokbuget; Josep Ribera; Wei Jiang; Susana Pulido; Erik Vandendries; Nathan Braniff; Elias Jabbour; Hagop Kantarjian
delete分享
delete收藏
One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis
deleteTargeted Oncology
IF4
delete2026-09-14
delete0
deleteOAAI
deleteToru Inoue; Kazuyuki Numakura; Takahiro Osawa; Sei Naito; Takuma Ishihara; Kojiro Ohba; Kosuke Ueda; Yuya Sekine; Masaharu Oki; Hirohito Naito; Haruka Miyata; Hiroshi Kikuchi; Shin Kobayashi; Shintaro Narita; Norihiko Tsuchiya; Mikio Sugimoto; Tsukasa Igawa; Toshitaka Shin
delete分享
delete收藏
Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion管理晚期非小细胞肺癌患者中与MET TKIs相关的不良事件：一场播客讨论
deleteTargeted Oncology
IF4
delete2026-09-12
delete0
deleteOAAI
deleteWade T. Iams; Narjust Florez
delete分享
delete收藏
Osimertinib Plus Platinum–Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC奥希替尼联合铂类–培美曲塞：既往未经治疗、EGFR突变、局部晚期或转移性NSCLC的综述
deleteTargeted Oncology
IF4
delete2026-09-11
delete0
PREAI
deleteAmy Zhuang-Yan; Yahiya Y. Syed
delete分享
delete收藏
Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure瑞戈非尼作为二线治疗与后线治疗在晚期肝细胞癌中的应用：一项多中心真实世界研究，并探索性分析先前免疫检查点抑制剂暴露情况
deleteTargeted Oncology
IF4
delete2026-09-01
delete0
PREAI
deleteKwon Yong Tak; Hee Sun Cho; Jaejun Lee; Kyeungmo Yang; Ahlim Lee; Ji Won Han; Soon Kyu Lee; Hyun Yang; Heechul Nam; Hee Yeon Kim; Seungwon Lee; Seok-Hwan Kim; Do Seon Song; Myeong Jun Song; Jung Hyun Kwon; UIm Chang; Soon Woo Nam; Chang Wook Kim; Jeong Won Jang; Si Hyun Bae; Hae Lim Lee; Pil Soo Sung
delete分享
delete收藏
Risk of Recurrence in Patients with HR+/HER2− Early Breast Cancer: A PodcastHR+/HER2−早期乳腺癌患者复发风险：一个播客
deleteTargeted Oncology
IF4
delete2026-08-31
delete0
deleteOAAI
deleteMaryam B. Lustberg; Megan-Claire Chase; Stacey Tinianov; Kevin Kalinsky
delete分享
delete收藏